Relationship between αGal epitope expression and decrease of tumorigenicity in pancreatic adenocarcinoma model

Molecular Carcinogenesis

Volumn 42, Issue 4, 2005, Pages 202-212

  Aubert, Muriel ^a,b   Crotte, Christian ^a   Benkoel, Liliane ^a   Panicot Dubois, Laurence ^a,c   Bernard, Jean Paul ^a   Lombardo, Dominique ^a   Sadoulet, Marie Odile ^a   Mas, Eric ^a  

^a INSERM   (France)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

1,3galactosyltransferase; Gal epitope; Cancer; Pancreas; Tumorigenicity

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; CARBOHYDRATE DERIVATIVE; EPITOPE; DISACCHARIDE; GALACTOSYL (1 3)GALACTOSE; GALACTOSYL-(1-3)GALACTOSE; GALACTOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER SURVIVAL; CARBOHYDRATE ANALYSIS; CARCINOGENICITY; CELL CLONE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GENETIC TRANSFECTION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; ADENOCARCINOMA; ANIMAL; GENETICS; HAMSTER; HUMAN; KINETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PLASMID; REFERENCE VALUE; SYRIAN HAMSTER; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CRICETINAE; DISACCHARIDES; DISEASE MODELS, ANIMAL; EPITOPES; GALACTOSYLTRANSFERASES; HUMANS; KINETICS; MESOCRICETUS; PANCREATIC NEOPLASMS; PLASMIDS; REFERENCE VALUES; TRANSFECTION;

EID: 17044366591     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20082     Document Type: Article

References (53)

1. Hakomori SI. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56:5309-5318.
2. Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clement M. ABH and Lewis histo-blood group antigens in cancer. APMIS 2001;109:9-31.
3. Huguier M, Mason NP. Treatment of cancer of the exocrine pancreas. Am J Surg 1999;177:257-265.
4. Ellenrieder V, Adler G, Gress TM. Invasion and metastasis in pancreatic cancer. Ann Oncol 1999;10:46-50.
5. Kim YS, Itzkowitz SH, Yuan M, et al. Lex and Ley antigen expression in human pancreatic cancer. Cancer Res 1988;48:475-482.
6. Itzkowitz S, Kjeldsen T, Friera A, Hakomori S, Yang US, Kim YS. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 1991;100:1691-1700.
7. Ichihara T, Sakamoto J, Nakao A, et al. Expression of blood group-related antigens in normal and malignant pancreatic tissue correlated with genotype of the patient defined by saliva glycoprotein. Cancer 1993;71:71-81.
8. Mas E, Pasqualini E, Caillol N, et al. Fucosyltransferase activities in human pancreatic tissue: Comparative study between cancer tissues and established tumoral cell lines. Glycobiology 1998;8:605-613.
9. Larsen RD, Rajan VP, Ruff MM, Kukowska-Latallo J, Cumming RD, Lowe J. Isolation of a cDNA encoding a murine UDPgalactose:β-D-galactosyl-1,4-N- acetyl-D-glucosamine α-1,3-galactosyltransferase: Expression cloning by gene transfer. Proc Natl Acad Sci USA 1989;86:8227-8231.
10. Joziasse DH, Shaper JH, VandenEijnden DH, VanTunen AJ, Shaper NL. Bovine alpha 1-3-galactosyltransferase: Isolation and characterization of a cDNA clone. Identification of homologous sequences in human genomic DNA. J Biol Chem 1989;264:14290-14297.
11. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1-3Gal epitope in primates. Proc Natl Acad Sci USA 1987;84:1369-1373.
12. Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and old world monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 1988;263:17755-17762.
13. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med 1984;160:1519-1531.
14. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988;56:1730-1737.
15. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 1993;82:2485-2493.
16. Koren E, Neethling FA, Richards S, et al. Binding and specificity of major immunoglobulin classes of preformed human anti-pig heart antibodies. Transpl Int 1993;6:351-353.
17. Cooper DK, Good AH, Koren E, et al. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: Relevance to discordant xenografting in man. Transpl Immunol 1993;1:198-205.
18. Joziasse DH, Oriol R. Xenotransplantation: The importance of the Galalpha1,3Gal epitope in hyperacute vascular rejection. Biochim Biophys Acta 1999;1455:403-418.
19. Good AH, Cooper DK, Malcolm AJ, et al. Identification of carbohydrate structures that bind human antiporcine antibodies: Implications for discordant xenografting in humans Transplant Proc 1992;24:559-562.
20. Oriol R, Ye Y, Koren E, Cooper DK. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation 1993;56:1433-1442.
21. Collins BH, Cotterell AH, McCurry KR, et al. Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection. J Immunol 1995;154:5500-5510.
22. Link CJ, Jr., Seregina T, Atchison R, Hall A, Muldoon R, Levy JP. Eliciting hyperacute xenograft response to treat human cancer: Alpha(1,3) galactosyltransferase gene therapy. Anticancer Res 1998;18:2301-2308.
23. Jäger U, Takeuchi Y, Porter CD. Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancer. Gene Therapy 1999;6:1073-1083.
24. Yoshimura N, Sawada T, Furusawa M, Fuchinoue S. Expression of xenoantigen transformed human cancer cells to be susceptible to antibody-mediated cell killing. Cancer Letts 2001;164:155-160.
25. Sawada T, Yamada O, Yoshimura N, Hatori K, Fuchinoue S, Teraoka S. Xenoantigen, an alphaGal epitope expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line. Cancer Cell Int 2002;2:14.
26. LaTemple DC, Abrams JT, Zhang SY, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: Studies in knockout mice for alpha1,3galactosyltransferase. Cancer Res 1999;59:3417-3423.
27. Chen ZC, Tanemura M, Galili U. Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in Pichia pastoris. Glycobiology 2001;11:577-586.
28. Deriy L, Chen ZC, Gao GP, Galili U. Expression of alpha-gal epitopes on HeLa cells transduced with adenovirus containing alpha1,3galactosyltransferase cDNA. Glycobiology 2002;12:135-144.
29. Aubert M, Crotte C, Bernard JP, Lombardo D, Sadoulet MO, Mas E. Decrease of human pancreatic cancer cells tumorigenicity by α1, 3Galactosyltransferase gene transfer. Int J Cancer 2003;107:91-918.
30. Schmied BM, Ulrich AB, Matsuzaki H, et al. Biologic instability of pancreatic cancer xenografts in the nude mouse. Carcinogenesis 2000;21:1121-1127.
31. Morioka CY, Saito S, Ohzawa K, et al. Subcutaneously inoculated cells and implanted pancreatic cancer tissue show different patterns of metastases in Syrian golden hamsters. J Pancreas 2000;1:183-190.
32. Chirgwin JM, Pryzbyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294-5299.
33. Hakomori SI. Antigen structure and genetic basis of histoblood groups A, B and O: Their changes associated with human cancer. Biochim Biophys Acta 1999;1473:247-266.
34. Hakomori SI. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci USA 2002;99:10231-10233.
35. LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyltransferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 1996;56:3069-3074.
36. Unfer RC, Hellrung D, Link CJ. Immunity to the α(1,3)galactosyl epitope provides protection in mice chalenged with colon cancer cells expressing α(1,3) galactosyltransferase: A novel suicide gene for cancer gene therapy. Cancer Res 2003;63:987-993.
37. Galili U. Autologous tumor vaccines processed to express alpha-gal epitopes: A practical approach to immunotherapy in cancer. Cancer Immunol Immunother 2004; published online.
38. Gorelik E, Duty L, Anaraki F, Galili U. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by alpha 1,3 galactosyltransferase genetransfection. Cancer Res 1995;55:4168-4173.
39. Schmied B, Liu G, Moyer MP, et al. Induction of adenocarcinoma from hamster pancreatic islet cells treated with N-nitrosobis(2-oxopropyl)amine in vitro. Carcinogenesis 1999;20:317-324.
40. Takiyama Y, Egami H, Pour PM. Blood group antigen expression in developing pancreas and in induced pancreatic cancer cells in Syrian hamsters. Carcinogenesis 1990;11:577-582.
41. Egami H, Chaney WG, Takiyama Y, Pour PM. Subcellular localization of blood group A substance produced by pancreatic adenocarcinoma induced in hamsters by N-nitrosobis (2-oxopropyl)amine (BOP) and by its cell line (PC-1). Carcinogenesis 1991;12:509-514.
42. Hirota M, Pour PM, Tempero MA, Chaney WG. Purification and analysis of glycoproteins bearing blood group-A determinants from hamster pancreatic ductal adenocarcinomas. Carcinogenesis 1992;13:1829-1833.
43. Hirota M, Egami H, Mogaki M, Kazakoff K, Chaney WG, Pour PM. Relationship between blood group-A antigen expression and malignant potential in hamster pancreatic cancers. Teratog Carcinog Mutagen 1993;13:217-224.
44. Itzkowitz SH, Yuan M, Ferrell LD, et al. Cancer-associated alterations of blood group antigen expression in the human pancreas. J Natl Cancer Inst 1987;79:425-434.
45. Kobayashi T, Uchida E, Tamura K, Yamanaka N. The relationship between the expression of blood group-related antigens and the cell proliferation of pancreatic carcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters. Surg Today 1993;23:908-916.
46. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999;1473:21-34.
47. Schaffert C, Pour PM, Chaney WG. Modification of blood group A expression in human pancreatic tumor cell lines by inhibitors of N-glycan processing. Int J Pancreatol 1997;21:21-29.
48. Ichikawa D, Handa K, Hakomori S. Histo-blood group A/B antigen deletion/reduction vs. continuous expression in human tumor cells as correlated with their malignancy. Int J Cancer 1998;76:284-289.
49. Keppler OT, Peter ME, Hinderlich S, et al. Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Glycobiology 1999;9:557-569.
50. Marionneau S, LeMoullac-Vaidye B, LePendu J. Expression of histo-blood group A antigen increases resistance to apoptosis and facilitates escape from immune control of rat colon carcinoma cells. Glycobiology 2002;12:851-856.
51. Labarriere N, Piau JP, Otry C, et al. H blood group antigen carried by CD44v modulates tumorigenicity of rate colon carcinoma cells. Cancer Res 1994;54:6275-6281.
52. Goupille C, Marionneau S, Bureau V, et al. alpha1,2Fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells. Glycobiology 2000;10:375-382.
53. Rose SD, MacDonald RJ. Evolutionary silencing of the human elastase I gene (ELA1). Hum Mol Genet 1997;6:897-903.